Skip to content

DANS study - diabetic autonomic neuropathy in patients undergoing surgery

Diabetic cardiovascular autonomic neuropathy in patients undergoing major gastrointestinal and cardiothoracic surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON21686
Enrollment
90
Registered
2014-11-24
Start date
2014-10-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiovascular autonomic neuropathy Diabetes mellitus Surgery

Interventions

On the day before surgery, patients will be subjected to 5 non-invasive tests to assess diabetic CAN, there will be no invasive test performed for study purposes.

Sponsors

Academic medical Centre, Department of Anaesthesiology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Willing and able to give written informed consent • (DM type 1 or type 2) • Scheduled for major gastro-intestinal- or cardiothoracic surgery • Age 18-85 years • Sinus rhythm

Exclusion criteria

Exclusion criteria: • Parkinson’s disease • Pure autonomic failure (formerly called idiopathic orthostatic hypotension) • Multiple system atrophy with autonomic failure (formerly called Shy-Drager syndrome) • Addison’s disease and hypopituitarism • Pheochromocytoma • Peripheral autonomic neuropathy (e.g., amyloid neuropathy, idiopathic autonomic neuropathy) • known cardiomyopathy • Extreme left ventricle hypertophy21 • Ejection fraction < 30%21 • Proven or suspected allergy for any of the medication used during induction of anaesthesia

Design outcomes

Primary

MeasureTime frame
-The prevalence of CAN in this surgical population -The relation between the stage of CAN and hemodynamic changes* * Hemodynamic changes are defined as: -Postinduction hypotension: mean arterial pressure <55 mmHg measured within first 10 minutes after start induction. -Postinduction mean arterial pressure; lowest mean blood pressure measured within first 10 minutes after start induction. -Postinduction blood pressure change: difference between highest mean arterial pressure before induction and lowest after induction before intubation. -Postinduction heart rate change: difference between minimum heart rate after induction and maximum heart rate before induction. -Maximum heart rate during tracheal intubation. -Maximum mean arterial blood pressure during tracheal intubation. -Perioperative inotropics; definition: total dose of inotropics (mcg/kg/hour) during surgery. Maximal dose during surgery (mcg/kg/hour) -Perioperative hypotension: mean arterial pressure < 55 mmHg at any time during the procedure. -Postoperative inotropics; definition: total dose (mcg/kg/hour) of inotropics after surgery.

Secondary

MeasureTime frame
- Ejection fraction postoperative compared to preoperatively in patients undergoing cardiac surgery, (pre- and postoperative transthoracic/transesophageal ultrasound images are made for standard care). - Mean glucose during surgery, glucose increase during surgery, hyperglycaemia (>10 mmol/l) during surgery (measured for standard care). - Plasma creatinine difference before and day 0, 1 and 2 after surgery (when measured for standard care). - Length of ICU and/or in-hospital stay - Length of inotropic dependent hours after surgery - In-hospital mortality < 30 days after surgery - Duration of DM - Presence of other DM related complications o Peripheral neuropathy (assessed with the Semmes-Weinstein test and tuning fork) o Presence of micro-albuminuria (from treating physician) o Retinopathy (based on last visit to ophthalmologist) - Relation between DM related complications and stage of CAN

Contacts

Public ContactJorinde Polderman
j.a.polderman@amc.uva.nl020-5669111 pager 57431

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)